Related Experiment Videos
Clinical aspects of intratumoral gene therapy
1Department of Microbiology and Immunology University of Arizona, Tucson 85724, USA. Akporiay@U.Arizona.edu
Abstract:
One of the major obstacles to the development of gene therapy for cancer is our inability to deliver genes to all targets within the body. Thus, effective methodology does not exist to deliver a gene intravenously with the expectation that it will selectively localize within the target tumor, will not localize in other tissues and will be expressed efficiently. While one can take advantage of tissue-specific promoters to activate the gene only in a given target tissue, only a small fraction of the vector will be taken up in the target tissue and expressed. Consequently, since accessible local or regional tumor masses are a major problem in many cancers, there has been a strong emphasis on clinical trials in intratumoral and peritumoral gene delivery.
Insights
Developing effective gene therapy for cancer faces challenges in gene delivery. Current methods struggle to target tumors specifically and efficiently, leading to a focus on direct tumor injection in clinical trials.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Gene therapy for cancer is hindered by inefficient and non-specific systemic gene delivery.
- Current intravenous delivery methods lack the ability to selectively target tumor tissues and ensure efficient gene expression.
- While tissue-specific promoters can activate genes in target tissues, vector uptake and expression remain limited.
Purpose of the Study:
- To address the critical challenge of targeted gene delivery in cancer gene therapy.
- To explore effective methodologies for achieving selective gene localization within tumor tissues.
- To improve the efficiency of gene expression in target cancer cells via novel delivery strategies.
Main Methods:
- Investigating advanced gene vector systems for enhanced tumor targeting.
- Developing strategies to improve intravenous delivery of therapeutic genes.
- Evaluating methods for increasing gene expression specifically within tumor cells while minimizing off-target effects.
Main Results:
- Limited systemic gene delivery to tumors remains a significant hurdle.
- Intratumoral and peritumoral gene delivery approaches are currently emphasized in clinical trials due to these limitations.
- Tissue-specific promoters show potential but have restricted vector uptake and expression.
Conclusions:
- Effective systemic gene delivery to all cancer targets is a major obstacle in gene therapy development.
- The lack of efficient and selective intravenous gene delivery necessitates alternative approaches.
- Intratumoral and peritumoral gene delivery strategies are currently the primary focus for clinical applications in cancer treatment.